Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Основные положения двойной антиагрегантной терапии и современные тенденции к ее изменению
________________________________________________
Erlih A.D. Main provisions of dual antiplatelet therapy and current trends in its change. Consilium Medicum. 2019; 21 (10): 79–84. DOI: 10.26442/20751753.2019.10.190547
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ключевые слова: двойная антиагрегантная терапия, ацетилсалициловая кислота, ингибитор P2Y12, острый коронарный синдром, коронарное стентирование, длительность, кровотечение.
________________________________________________
Key words: double antiplatelet therapy, acetylsalicylic acid, P2Y12 inhibitor, acute coronary syndrome, coronary stenting, duration, bleeding.
2. Wiviott SD, Braunwald E, McCabe CH et al.; for the TRITON–TIMI 38 Investigators. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001–15.
3. Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11): 1045–57.
4. Mauri L Kereiakes DJ, Yeh RW et al. for the DAPT Study Investigators. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med 2014; 371: 2155–66.
5. Bonaca MP, Bhatt DL, Cohen M et al.; for the PEGASUS-TIMI-54 Steering Committee and Investigators. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med 2015; 372: 1791–800.
6. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018; 39: 213–54.
7. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87–165.
8. Costa F, van Klaveren D, James S et al.; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389: 1025–34.
9. Yeh RW, Secemsky EA, Kereiakes DJ et al.; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA 2016; 315 (16): 1735–49.
10. Urban P, Mehran R, Colleran R et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. A consensus document from the academic research consortium for high bleeding risk. Circulation 2019; 140: 240–61.
11. Kikkert WJ, Damman P. Optimal duration of dual antiplatelet therapy for coronary artery disease. Neth Heart J 2018; 26 (8): 321–33.
12. Vranckx P, Valgimigli M, Juni P et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomized superiority trial. Lancet 2018; 392 (10151): 940–9.
13. Watanabe H, Domei T, Morimoto T et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI. The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019; 321 (24): 2414–27.
14. Hahn JY, Song YB, Oh J-H et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention. The SMART-CHOICE Randomized Clinical Trial. JAMA 2019; 321 (24): 2428–37.
15. Dewilde WJ, Oirbans T, Verheugt FW et al.; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381 (9872): 1107–15.
16. Gibson CM, Mehran R, Bode C et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016; 375: 2423–34.
17. Cannon CP, Bhatt DL, Oldgren J et al.; for the RE-DUAL PCI Steering Committee and Investigators. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017; 377: 1513–24.
18. Lopes RD, Heizer G, Aronson R et al.; for the AUGUSTUS Investigators. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med 2019; 380: 1509–24.
________________________________________________
1. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N Engl J Med 2001; 345: 494–502.
2. Wiviott SD, Braunwald E, McCabe CH et al.; for the TRITON–TIMI 38 Investigators. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001–15.
3. Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11): 1045–57.
4. Mauri L Kereiakes DJ, Yeh RW et al. for the DAPT Study Investigators. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med 2014; 371: 2155–66.
5. Bonaca MP, Bhatt DL, Cohen M et al.; for the PEGASUS-TIMI-54 Steering Committee and Investigators. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. N Engl J Med 2015; 372: 1791–800.
6. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J 2018; 39: 213–54.
7. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87–165.
8. Costa F, van Klaveren D, James S et al.; PRECISE-DAPT Study Investigators. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017; 389: 1025–34.
9. Yeh RW, Secemsky EA, Kereiakes DJ et al.; DAPT Study Investigators. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA 2016; 315 (16): 1735–49.
10. Urban P, Mehran R, Colleran R et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. A consensus document from the academic research consortium for high bleeding risk. Circulation 2019; 140: 240–61.
11. Kikkert WJ, Damman P. Optimal duration of dual antiplatelet therapy for coronary artery disease. Neth Heart J 2018; 26 (8): 321–33.
12. Vranckx P, Valgimigli M, Juni P et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicenter, open-label, randomized superiority trial. Lancet 2018; 392 (10151): 940–9.
13. Watanabe H, Domei T, Morimoto T et al. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI. The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019; 321 (24): 2414–27.
14. Hahn JY, Song YB, Oh J-H et al. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention. The SMART-CHOICE Randomized Clinical Trial. JAMA 2019; 321 (24): 2428–37.
15. Dewilde WJ, Oirbans T, Verheugt FW et al.; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381 (9872): 1107–15.
16. Gibson CM, Mehran R, Bode C et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016; 375: 2423–34.
17. Cannon CP, Bhatt DL, Oldgren J et al.; for the RE-DUAL PCI Steering Committee and Investigators. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017; 377: 1513–24.
18. Lopes RD, Heizer G, Aronson R et al.; for the AUGUSTUS Investigators. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med 2019; 380: 1509–24.
ГБУЗ «Городская клиническая больница №29 им. Н.Э. Баумана» Департамента здравоохранения г. Москвы, Москва, Россия
alexeyerlikh@gmail.com
________________________________________________
Aleksei D. Erlih
Bauman City Clinical Hospital №29, Moscow, Russia
alexeyerlikh@gmail.com